MOTS-c Peptide Dosage Guide: Ranges, Exercise Research & Reconstitution

MOTS-c at a glance

What it is

A 16-amino-acid peptide encoded by a short open reading frame inside the mitochondrial 12S rRNA gene - one of the mitochondrial-derived peptides, alongside humanin. C101H152N28O22S2, average molecular weight approximately 2,174.6 Da, PubChem CID 146675088.

Where the name comes from

Mitochondrial Open reading frame of the Twelve S rRNA type-c. It is descriptive of the gene it was found in, not of what it does.

Discovered

Lee C et al., Cell Metabolism 2015 - the paper that identified the reading frame, named the peptide and established its metabolic effects in mice.

Established mechanism

Inhibits the folate cycle and the de novo purine biosynthesis tethered to it, which raises AICAR and activates AMPK. Under metabolic stress it also translocates into the nucleus and regulates nuclear gene expression, including antioxidant-response-element genes, in an AMPK-dependent way - making it a genuine mitochondrial-to-nuclear signal.

Primary tissue

Skeletal muscle. This is where the discovery paper located its main action and where the exercise literature concentrates.

The exercise finding

Exercise induces endogenous MOTS-c in human skeletal muscle and in circulation - that part is human data. The performance and healthspan effects of giving MOTS-c are mouse data. Keeping those two apart is the single most common error in writing about this compound.

Human trial status

None this guide is prepared to cite. A registry entry previously listed here as the first registered interventional trial, NCT07505745, was withdrawn on 2026-08-26 on provenance grounds: it carries no results and no publication, and the account that filed it also filed a TB-500 entry whose own summary calls itself a fictional example record.

Commonly reported range

Roughly 5-10 mg per administration in research-community discussion, with no published human dose behind it. Note that a 10 mg amount is constrained by syringe capacity - see the reconstitution section.

Regulatory status

Not approved by FDA or any comparable regulator for any indication. Sold and discussed for research and educational use only. Not specifically named on the WADA Prohibited List as of this writing, which is not the same as being permitted - verify current status directly.

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

The interesting thing about MOTS-c is where it was found. Mitochondria carry their own small circular genome, a leftover of the bacterial ancestry of the organelle, and for decades that genome was described as containing 37 genes: 13 protein-coding, 22 transfer RNAs and 2 ribosomal RNAs. The ribosomal RNA genes were understood as structural - they make the RNA scaffolding of the mitochondrial ribosome and nothing else. Then humanin was identified inside the 16S rRNA gene, which raised the obvious question of whether other short open reading frames were hiding in mitochondrial DNA. Lee and colleagues went looking in the 12S rRNA gene and found one, encoding a 16-residue peptide they named MOTS-c: mitochondrial open reading frame of the twelve S rRNA type-c. The name describes the address, not the function. That origin is not trivia. It means MOTS-c is an endogenous molecule that circulates in human plasma, that is expressed in tissues alongside mitochondria, and whose levels decline with age. It also means the mitochondrial genome encodes signalling factors rather than only structural and respiratory components - a genuine change in how mitochondrial-nuclear communication is understood, and the reason this peptide gets attention in aging biology rather than only in metabolism. The mechanism established in the discovery paper is specific and slightly counterintuitive. MOTS-c targets skeletal muscle, and its cellular action is inhibition of the folate cycle and of the de novo purine biosynthesis pathway tethered to it. Blocking that pathway causes AICAR - an intermediate in purine synthesis - to accumulate, and AICAR is an AMPK activator. So MOTS-c activates AMPK indirectly, through a metabolic intermediate, rather than by binding a receptor. AMPK is the cell's low-energy sensor: when it is activated, the cell shifts toward glucose uptake, fatty-acid oxidation and catabolic energy generation and away from anabolic synthesis. In mice, MOTS-c treatment prevented both age-dependent and high-fat-diet-induced insulin resistance, and prevented diet-induced obesity. The second mechanistic layer arrived in 2018 and is the more conceptually significant one. Kim and colleagues showed that under metabolic stress - specifically glucose restriction - MOTS-c translocates from the cytoplasm into the nucleus, where it regulates a broad set of nuclear genes in an AMPK-dependent manner. Among the genes it influences are those carrying antioxidant response elements, and MOTS-c was found to interact with the stress-responsive transcription factors that regulate them, including NRF2. The framing the authors gave it is worth quoting in substance: the nuclear genome was already known to regulate the mitochondrial genome, and this demonstrates regulation running the other way, with the two genomes having co-evolved to encode factors that cross-regulate each other. A peptide encoded in mitochondrial DNA that physically enters the nucleus and changes nuclear transcription is a retrograde signal in the strongest sense. The exercise connection follows from the stress-response logic. MOTS-c expression rises in skeletal muscle, in the circulation and in the hypothalamus in response to exercise, which fits a peptide whose trigger is metabolic stress and whose action is AMPK-linked. This is the basis of the mitohormesis framing that MOTS-c is usually discussed under: low levels of mitochondrial stress produce adaptive responses, and mitochondrial-derived peptides are among the messengers carrying those responses beyond the organelle. Exogenous MOTS-c has also been reported to stimulate thermogenesis in subcutaneous white adipose tissue in animal work, which is a separate arm from the muscle effects. A genetic strand exists and is routinely overstated. Fuku and colleagues noted that a polymorphism in the MOTS-c-encoding region of mitochondrial DNA, m.1382A>C, is specific to Northeast Asian populations, and proposed that it might be among the mechanisms contributing to Japanese longevity. That paper is explicitly a hypothesis - its own title ends in a question mark and its text says more research is needed. It is frequently cited on commercial pages as though it demonstrated that a MOTS-c variant causes exceptional lifespan, which it does not. What none of this mechanistic work establishes is that administering MOTS-c does anything in a human being. That question has only just been put to a controlled test, and the test is still running.

Researched effects

The effects reported for MOTS-c divide cleanly into two categories that are constantly conflated, so it is worth separating them explicitly before listing anything. Category one is what endogenous MOTS-c does, and here there is genuine human data. Acute high-intensity exercise raises MOTS-c concentrations in human skeletal muscle and in plasma - this has been measured in people, not inferred from mice. Circulating MOTS-c declines with age. That is the human evidence base, and it is observational: it establishes that MOTS-c is an exercise-responsive endogenous peptide whose levels fall over a lifespan. Category two is what happens when MOTS-c is administered, and that column is entirely animal work. The headline results are substantial within that limit. Reynolds and colleagues reported that MOTS-c significantly enhanced physical performance in mice at three ages - young at 2 months, middle-aged at 12 months and old at 22 months - and, in the finding that gets quoted most, that treatment initiated in late life at 23.5 months on an intermittent schedule of three times per week increased both physical capacity and healthspan. The same paper documented effects on nuclear gene expression relating to metabolism and proteostasis, on skeletal muscle metabolism, and on myoblast adaptation to metabolic stress. The metabolic results from the discovery paper sit alongside these: prevention of age-dependent and diet-induced insulin resistance and of diet-induced obesity in mice. It is worth noticing where the community's three-times-weekly dosing convention comes from, because almost nobody says. It comes from that mouse study's intermittent late-life schedule. There is no human study establishing that frequency, or any other. Beyond muscle and metabolism, the animal literature has broadened in directions that are rarely mentioned on commercial pages. MOTS-c has been reported to relieve hyperglycaemia and insulin resistance in a mouse model of gestational diabetes, improving glucose tolerance and insulin sensitivity and protecting pancreatic beta cells from chemical injury. And a 2024 study reported that MOTS-c levels are reduced in serum and tumour tissue from ovarian cancer patients and associated with worse prognosis, with exogenous MOTS-c inhibiting proliferation, migration and invasion in ovarian cancer cells through a LARS1 and USP7 mechanism, and showing anti-tumour effect without systemic toxicity in vivo. These are single-group findings in specific models and are included here for completeness rather than as anything actionable. What the training literature does not show is worth stating as clearly as what it does. Whether regular exercise training produces a chronic change in MOTS-c levels - as opposed to the acute post-exercise spike - is genuinely unresolved, with conflicting results that appear to depend on the mode, duration and intensity of the training programme and on participant characteristics. Anyone reading a confident claim that training raises baseline MOTS-c is reading past a disagreement in the literature. And until very recently, the field's own summary of the translational position was blunt: reviews as recent as 2023 stated that no effective method of applying MOTS-c in the clinic had been developed. That is the honest backdrop, and the trial registry does not currently change it - the evidence section sets out why the entry once cited here was withdrawn. Nothing here is a claim that MOTS-c treats, prevents or improves any condition in people, and nothing here is medical advice.

Dosage — reported ranges (overview)

There is no established human dose for MOTS-c. No controlled trial this guide is prepared to cite has administered the peptide to people, so no dose has been tested in humans and none can be derived from the clinical record. The figures circulating in research-community settings centre on roughly 5 to 10 mg per administration. That range has no published derivation. It was not identified in a dose-ranging study, it does not correspond to any animal dose converted by body-surface-area scaling, and it does not come from any registered trial. It is community convention, and it should be read as a description of practice rather than as a finding. The frequency convention has a clearer, and more instructive, origin. Research-community protocols very commonly specify three administrations per week, and that number traces directly to a single mouse experiment: the late-life intervention in Reynolds 2021, which used an intermittent three-times-weekly schedule in 23.5-month-old animals and reported increased physical capacity and healthspan. That is a real and interesting result, and it is a mouse result. When a human protocol specifies exactly the same cadence, it is inheriting the design of a rodent healthspan study rather than reflecting anything measured in people. The animal literature that does report doses generally works in milligrams per kilogram given intraperitoneally or subcutaneously, which does not convert cleanly to a fixed human milligram figure - and the discovery paper's most striking metabolic results came from treatment regimes designed to test mechanism in mice, not to establish exposure targets. Anyone presenting a human MOTS-c dose as evidence-based is presenting something that does not exist yet. One practical consideration deserves more attention than it usually gets, because it constrains the reported range in a way that is easy to miss until the vial is in front of you. MOTS-c is a comparatively large peptide for this market - about 2,175 Da, roughly six times the mass of a tripeptide like KPV - and the commonly discussed amounts are in milligrams rather than micrograms. A 10 mg vial reconstituted with 2 mL yields 5 mg/mL, which puts a 5 mg amount at exactly 100 units: a completely full 1 mL U-100 insulin syringe. Reconstitute the same vial with 3 mL and 5 mg no longer fits in one syringe at all. This is not a theoretical concern; it is the reason reconstitution volumes for this compound are narrower than for most, and it is worked through in the reconstitution section. On cycling, there is nothing to report from the evidence side. The community habit of running defined blocks with breaks has no counterpart in the published work, where animal studies ran continuously or on the intermittent schedule described above, and the human trial runs 12 weeks continuously. Everything in this section describes what has been reported and published, for educational purposes. None of it is a recommended dose, a protocol, or a suggestion that anyone use this compound.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

MOTS-c reconstitution has a constraint most peptides do not, and it is worth understanding before choosing a water volume rather than after. The peptide is comparatively heavy - about 2,175 Da - and the amounts discussed in research settings are in milligrams, so the volume you draw is larger than for a microgram-dosed compound and can run into the physical capacity of the syringe. A U-100 insulin syringe holds 1 mL across 100 units, so 100 units is the hard ceiling for a single administration. With a 10 mg vial, a 5 mg amount is exactly 100 units at 2 mL of bacteriostatic water and does not fit in one syringe at any larger volume; a 10 mg amount only fits at 1 mL or less. That is why the table below stops at 2 mL, and why the examples shown are 2 mg and 5 mg - they are the amounts that remain drawable across the whole range. The arithmetic itself is standard: concentration in mg per mL is vial mg divided by mL of bacteriostatic water added, and units are (target mg / concentration in mg per mL) x 100. The two example amounts are illustrations of the arithmetic, not recommendations. The calculator on this page will run the same computation for any vial size and volume, including combinations that exceed one syringe.

This is concentration math, not a dose recommendation.

Injection / administration basics

Where subcutaneous administration is described for MOTS-c in research settings it follows the standard pattern for a reconstituted peptide: a U-100 insulin syringe, aseptic technique, a subcutaneous site, and rotation between sites rather than repeated use of one. General handling concepts - keeping the vial stopper clean, drawing without introducing air, avoiding tissue that is bruised, hardened or scarred - are covered here as general information. A worked step-by-step version, a printable protocol sheet and a blank injection log come with All-Access Lifetime. The syringe-capacity point from the reconstitution section is genuinely an administration issue rather than an arithmetic curiosity, and it is the one thing about handling this compound that differs from the norm. Because the amounts discussed are in milligrams and the peptide is heavy, the drawn volume can approach or exceed 1 mL. A volume at or near the full capacity of a U-100 syringe is also a large subcutaneous bolus, and larger subcutaneous volumes are more likely to produce local discomfort and slower absorption than small ones. The practical consequence is that reconstitution volume and administration are coupled for MOTS-c in a way they are not for microgram-dosed peptides: choosing a larger water volume for convenience can produce an amount that has to be split across two injections. The human trial now recruiting uses the subcutaneous route, which at least means the route in question is the one being tested rather than one extrapolated from animal work - though the trial's dose and schedule are not public in the registry entry, so it cannot be used as a reference for either. None of this is an administration protocol and none of it is medical advice. MOTS-c is not approved for use in any person, there is no approved dose or route, and a qualified professional should direct anything anyone actually does.

Half-life & frequency rationale

No published human pharmacokinetic study reports a half-life for MOTS-c. Targeted searches for pharmacokinetics, half-life and plasma clearance of this peptide return nothing, and there is no approved product whose label would supply the figure. Any specific number quoted for MOTS-c half-life is not traceable to a measurement in people. What can be said, carefully, comes from two directions. The first is structural. MOTS-c is a 16-residue unmodified peptide with no half-life-extending modification of the kind attached to peptides designed for weekly administration - no fatty-acid acylation, no PEGylation, no albumin-binding moiety. Peptides of that description are generally cleared on the order of minutes to a few hours by peptidase degradation and renal filtration. This is a structural expectation, not a measurement, and it should be labelled as one. The second is behavioural, and more interesting. The endogenous peptide's dynamics have been observed in humans in the exercise context: MOTS-c rises in skeletal muscle and plasma after acute high-intensity exercise, which is a stimulus-response pattern on the timescale of a training session rather than of days. Whether chronic training shifts baseline levels is unresolved in the literature. Neither observation gives a clearance rate, but both are consistent with a molecule that responds and resolves quickly rather than persisting. The most honest framing of the frequency question is therefore that the three-times-weekly convention in community protocols does not rest on a duration-of-action measurement at all. It rests on the schedule used in one mouse healthspan experiment. That may or may not be a sensible cadence for a peptide with these properties; what it is not is a pharmacokinetically derived interval, and it should not be presented as one.

Stacking — overview

MOTS-c appears in stack discussion under a metabolic-and-mitochondrial theme, most often alongside SS-31, NAD+ precursors and 5-Amino-1MQ. The grouping is thematic - these compounds are discussed together because they are all described as mitochondrial or metabolic, not because any interaction between them has been studied. No controlled study has tested MOTS-c in combination with anything. There is one combination question here that is more substantive than the usual stack reasoning, and it is worth stating because it cuts against a common assumption. MOTS-c works by activating AMPK. Several other compounds and interventions in the same conversation also converge on AMPK - and so, notably, does exercise itself, which is the physiological stimulus that raises endogenous MOTS-c in the first place. Whether stacking multiple AMPK-directed inputs is additive, redundant or counterproductive is genuinely unknown, and the honest position is that adding a second AMPK-linked input to a pathway already being driven is not self-evidently a stronger intervention. This is the same class-collision question the Stacking Guide applies to receptor-sharing peptides, applied to a shared downstream node rather than a shared receptor. The exercise interaction deserves the same scepticism in the opposite direction. Because exercise induces endogenous MOTS-c, it is sometimes argued that exogenous MOTS-c and training are naturally complementary. It could equally be argued that a training stimulus already producing the signal makes supplying more of it redundant. Neither argument has been tested, and the mouse performance data - which is what the complementarity claim is usually built on - did not compare treated-plus-trained against trained alone. The cross-compound Stacking Guide covers combination logic, class and pathway collisions, and blend arithmetic across the library. Paid access to this guide adds the MOTS-c Stacking Module alongside the printable protocol sheet and injection log.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Lyophilised and unopened: store cold and dark. Long-term storage is typically described at -20 C in a freezer, with refrigeration generally described as adequate for shorter periods. Keep the vial in its carton, since peptides in general are light-sensitive.
• After reconstitution with bacteriostatic water: refrigerate at roughly 2-8 C. The usable window commonly reported in research settings is around two to four weeks; the benzyl alcohol in bacteriostatic water is what makes a multi-withdrawal window possible at all, by suppressing microbial growth between entries.
• Do not freeze a reconstituted vial. Freeze-thaw cycling is a recognised degradation route for peptides in solution and is the most common avoidable handling error.
• Choose the reconstitution volume before mixing, not after. Because MOTS-c amounts are in milligrams, the water volume determines whether a given amount fits in a single U-100 syringe - and once the vial is reconstituted the concentration cannot be changed.
• Add bacteriostatic water slowly down the inside wall of the vial rather than onto the powder, swirl rather than shake, keep the stopper clean and use a fresh needle for each withdrawal. Mechanical agitation causes peptide aggregation, and no preservative compensates for repeated entry with a contaminated needle.

Evidence File

The MOTS-c Evidence File: 254 Papers, Nine Registry Records, and Not One Published Human Dose

MOTS-c is unusual among research-market compounds in that its scientific literature is genuinely large and genuinely good — 254 PubMed records, a 2015 discovery paper in a major journal, a real mechanism, and a naturally occurring human genetic variant that has been studied in its own right. What that literature never does is give the peptide to a person. This file separates the two questions the market runs together: what is known about MOTS-c as a molecule your own mitochondria make, and what is known about injecting it. The first has a decade of work behind it. The second is empty — and the one registry record that appeared to fill it has been withdrawn as evidence by this guide, on provenance grounds set out in full below. Every search is named so that every claim here can be reproduced rather than taken on trust.

• 9 registry records found across 4 named search terms
• 0 of the 9 establish that MOTS-c has been given to anyone
• 254 PubMed records; 5 tagged as clinical trials; 0 of those 5 gave the peptide
• 1 record withdrawn — its filing account has 8, three self-declared fictional

Sourcing File

The MOTS-c Sourcing File: A Sequence That Verifies Itself, Two Methionines, and a Variant Routine Mass Spec Cannot See

MOTS-c is one of the more checkable peptides in this library, and one of the easier ones to get quietly wrong. Its sixteen-residue sequence reproduces its published molecular formula exactly, which means a reader with a certificate in front of them can verify the identity claim arithmetically rather than trusting it — this file shows that calculation worked through. It also has two specific liabilities that generic COA advice will not catch: a pair of methionine residues that oxidise and shift the mass in predictable steps, and a naturally occurring human sequence variant that differs from the reference peptide by four hundredths of a dalton, which is comfortably inside the error of the mass spectrometry most suppliers actually run.

• Sequence MRWQEMGYIFYPRKLR verified against PubChem formula — exact match
• 2 methionines: +15.99 Da per oxidation, two steps possible
• K14Q variant differs by 0.043 Da — 20 ppm on a 2,174 Da peptide
• 0 FDA-approved products; no pharmacopoeial monograph to test against

Benefit & Outcome Review

The MOTS-c Benefit and Outcome Review: Every Marketed Claim Against What Was Measured, and in What Species

This review takes the claims made for MOTS-c one at a time and asks the same four questions of each: what was measured, in whom or in what, how large the effect was, and whether the compound was administered or merely observed. That last question does most of the work here. MOTS-c has an unusually respectable scientific literature, and an unusually wide gap between what that literature establishes about the peptide your mitochondria make and what is claimed for the peptide in a vial. Where a claim is supported, this review says so plainly. Where the supporting evidence is an association running in the opposite direction to the claim, it says that too.

• 5 marketed claims assessed against the primary record
• 0 rest on published human administration data
• 1 is supported by evidence pointing the opposite way
• 0 have a human trial pending — the one on the register was withdrawn

Guide FAQ

Quick answers about guide scope, access, and educational use context.